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In 2015 and 2016, Zika virus (ZIKV) swept through dengue virus (DENV) endemic areas of
Latin America. These viruses are of the same family, share a vector and may interact com-
petitively or synergistically through human immune responses. We examine dengue inci-
dence from Brazil and Colombia before, during, and after the Zika epidemic. We find evidence
that dengue incidence was atypically low in 2017 in both countries. We investigate whether
subnational Zika incidence is associated with changes in dengue incidence and find mixed
results. Using simulations with multiple assumptions of interactions between DENV and
ZIKV, we find cross-protection suppresses incidence of dengue following Zika outbreaks and
low periods of dengue incidence are followed by resurgence. Our simulations suggest cor-
relations in DENV and ZIKV reproduction numbers could complicate associations between
ZIKV incidence and post-ZIKV DENV incidence and that periods of low dengue incidence are
followed by large increases in dengue incidence.
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In 2015 and 2016, Zika virus (ZIKV) swept through many LatinAmerican countries1 where dengue virus (DENV) is endemic.Following this epidemic, many locations appeared to experi-
ence abnormally low dengue incidence. DENV and ZIKV share a
vector2,3 and are both flaviviruses. Evidence suggests these viruses
may interact competitively or synergistically through human
immune responses: via antibodies in the case of non-overlapping
infections4–10 or innate defenses during co-infections11,12. Con-
current infections in the vector could also potentially alter viral
fitness though the low prevalence of infection in mosquitos at any
time and thus the low rate at which concurrent infections occur is
likely to minimize the impact of this interaction12–14. It is also
possible that these viruses may have no biological interaction
whatsoever. Changes in surveillance and control in response to
Zika1,15 could affect reported dengue cases. Conditions (cli-
mate16, vector abundance) that favor Zika may be similar to those
favoring dengue.
Epidemics of emerging pathogens have the potential to disrupt
the ecology of other circulating pathogens. ZIKV was identified in
the Americas in Brazil in late 201517, though phylogeographic
analyses suggest ZIKV may have arrived as early as mid-201318,
entering northeast Brazil in early 201419. The outbreak in the
Americas was extensive, affecting 48 countries and territories up
through December 201720. Serological evidence has found rates of
infection ranging from 56% (Nicaragua21) to 63% (Salvador,
Brazil22). These are comparable to seroprevalence in previous
ZIKV outbreaks; 73% in Yap Island, Micronesia23, 49% in French
Polynesia24. Associations between ZIKV infection and severe
disease outcomes such as microcephaly and Guillain-Barre ́ syn-
drome were recognized by the WHO in March 20161, prompting
intensified surveillance and control efforts.
Since 2016, Zika incidence in Brazil has dropped precipitously,
from over 200,000 probable cases in 2016 to 18,548 in 201725. In
Colombia incidence dropped from approximately 90,000 in 2016
to 1641 in 201725. These reductions are likely the result of wide-
spread immunity throughout affected populations, leaving few
individuals susceptible to infection. Multiple human and animal
studies show that ZIKV induces potently neutralizing antibody
responses26,27, suggesting enduring ZIKV-specific immunity28.
The primary ZIKV vectors, Aedes aegypti and Aedes
albopictus2,3,29, also transmit chikungunya virus (CHIKV) and
DENV. In contrast to CHIKV (an alphavirus), DENV and ZIKV
are genetically similar flaviviruses8. DENV exists as four anti-
genically distinct serotypes (DENV1-4). When an individual is
infected by DENV, there is a period of cross-protection from
infection by other serotypes30. After the period of cross-protec-
tion, subsequent infections with different serotypes can result in
more severe disease due to antibody dependent enhancement
(ADE)31,32. It has been speculated that, due to the similarity
between DENV and ZIKV, immunity to one of these viruses
may alter the chance of infection or probability of severe disease
following exposure to the other virus. Current evidence
supports both the potential for enhancement4–7 and for cross-
protection5,7–10.
Here, we examine data from Brazil (1999–2017)25,33,34 and
Colombia (2007–2017)25,35,36 to determine whether dengue
incidence has been atypical since the emergence of ZIKV. We
demonstrate that dengue incidence was significantly lower than
expected in both countries in 2017. Despite these unprecedented
low periods, we do not find a negative association between
cumulative Zika incidence and biweekly dengue incidence in
either country. To gain insight into how immunological inter-
actions would impact the relationship between ZIKV and DENV
incidence in this period, we use a stochastic compartmental
model of the four DENV serotypes and ZIKV under multiple
assumptions. In almost all simulations incorporating strong
ZIKV cross-protection against subsequent DENV infection, ZIKV
epidemics are followed by a trough in dengue incidence, followed
by a larger than average peak in DENV incidence. Correlated
hazards of DENV and ZIKV transmission may complicate the
relationship between ZIKV incidence and resulting dengue inci-
dence. Our simulations consistently show that periods of low
dengue incidence are followed by large increases in dengue
incidence.
Results
Departures from expected dengue incidence. At the population
level, the large ZIKV epidemic could plausibly have led to either
increases or decreases in dengue cases. To determine if either was
the case, we compared dengue surveillance data from before,
during, and after the arrival of ZIKV. We constructed time series
of probable case counts for each state in Brazil (1999–2017)25,33,34
and department in Colombia (2007–2017)25,35,36 (see “Methods”,
Fig. 1b, d, Supplementary Fig. 1). In 2017, Brazil had the lowest
annual incidence rate (IR) of dengue since 2005 (Fig. 1a) and
Colombia had the lowest annual dengue incidence since 2007 (the
first year of available data) (Fig. 1c).
We quantified the probability of departures arising by chance
from expected dengue incidence using time series models with
seasonal variation in autocorrelative effects (see Methods and
Supplementary Figs. 2–4 for further details on model implemen-
tation and predictive ability). Biweeks with atypically large
incidence occurred significantly more often than expected in
Brazil in 2015 (Fig. 2a, b). In 2017, Brazil experienced an increase
in both atypically high and atypically low biweeks compared to
expectation. In Colombia, a significant increase in atypically low
biweeks was observed in 2016 and 2017 (Fig. 2c, d) (see
“Methods” and Supplementary Figs. 5 and 6 for further details).
Characterizing departures with hierarchical models. To attempt
to explain the significant departures that we saw in each location,
we built a set of hierarchical time series models that incorporated
a number of subnational covariates. These models forecasted
dengue incidence using combinations of seasonal dengue terms,
year effects, and recent incidence of Zika. For a baseline, we also
fit models incorporating chikungunya incidence. CHIKV shares
climate and vector determinants as DENV and ZIKV but is of a
different viral family and thus is not expected to interact
immunologically with flaviviruses.
In models incorporating year effects, we found that biweekly
expected dengue incidence in 2015 was higher than that of
corresponding biweeks in other years in both Brazil (mean: 2.21-
fold increase, 95% CrI: 1.45–3.37) and Colombia (mean: 1.11-fold
increase, 95% CrI: 0.96–1.29). In contrast, we found that biweekly
dengue incidence in 2017 was lower in both Brazil (relative
incidence mean: 0.63, 95% CrI: 0.46–0.86) and Colombia (relative
incidence mean: 0.23, 95% CrI: 0.18–0.29). At the subnational-
level there are differences in the significance and direction of
these effects (Fig. 3b, d), with the exception of 2017 in Colombia,
where there is a significant reduction in biweekly dengue
incidence in all departments (Fig. 3d).
We found a positive association between the previous biweek’s
Zika incidence and dengue transmission potential in Brazil (mean
coefficient: 0.16, 95% CrI: 0.05–0.26, Fig. 3a). Putting this
coefficient in context, 1000 Zika cases observed in the previous
biweek translates to a multiplicative increase of about three times
as many expected dengue cases in the following biweek (mean:
2.92, 95% CrI: 1.40–6.15). We also found a positive association
between cumulative Zika incidence on dengue transmission
potential in Brazil (mean coefficient: 0.04, 95% CrI: 0.003, 0.08).
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No significant associations were found between Zika incidence
and dengue transmission potential in Colombia.
In Brazil, cumulative (mean coefficient: 0.04, 95% CrI:
0.01–0.08, Fig. 3a) and biweekly (mean coefficient: 0.11, 95%
CrI: 0.04–0.17, Fig. 3a) chikungunya incidence were positively
associated with expected dengue transmission in the following
biweek (Fig. 3a, c, Supplementary Fig. 7). No significant
association were found between chikungunya incidence and
dengue transmission potential in Colombia.
In Brazil, states with positive effects of Zika on dengue
transmission potential often observed positive effects of chikun-
gunya on dengue (Supplementary Fig. 7). Totals of suspected Zika
and suspected chikungunya cases at state- and department-level
were positively correlated (Supplementary Fig. 8), consistent with
potentially shared environmental suitability conditions for
transmission of these viruses.
We tested whether the direction of country-level effects was an
artifact of our model implementation, by replacing 2015 to 2017
with a random three consecutive years of data preceding 2015
and then repeating the model fitting procedure. We did not find
agreement in the directionality of the country-level effects across
the resulting models (see Supplementary Fig. 9), supporting our
main results.
Simulations incorporating immune-mediated interactions. We
tested whether immune-mediated interactions between DENV
and ZIKV could produce the dengue dynamics observed in Brazil
and Colombia by simulating the arrival of Zika in a dengue
endemic population (Fig. 4 and Supplementary Figs. 10–12). We
used a stochastic compartmental model that incorporated com-
binations of cross-protection or enhancement between the two
viruses (see “Methods” for further details). We performed
simulations in which ZIKV was introduced to a population in
which DENV was in a stable state as well as simulations that
incorporated the sequential introduction of dengue over the
decades preceding the ZIKV introduction reflecting the observed
detection of DENV serotypes37 (see Supplementary Fig. 12 for
sample simulations from both settings). In simulations where
ZIKV infection temporarily reduces an individual’s risk of DENV
infection by 80%, Zika epidemics are followed by a trough in
dengue incidence ranging from 2.2 years to 3.5 years depending
on the enhancement scenario (Fig. 4i–l and Supplementary
Table 1). Even in the absence of enhancement between DENV
and ZIKV, multiple simulations showed increases in dengue after
troughs ranging from a 1.3-fold increase to a 2.7-fold increase
(Fig. 4). Based on our simulations, which assumed that cross-
protection lasts one year on average, the time until dengue
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Fig. 1 Estimated dengue incidence in Brazil and Colombia (per 100,000). Note that Zika incidence was not systematically reported prior to 2016 in Brazil
(a) or late 2015 in Colombia (c) and that Chikungunya was not systematically reported prior to 2015 and late 2014 respectively in Brazil (a) and Colombia
(c). In Brazil, updated data from the following year’s bulletin for 2014 to Epiweek 42, 2017 is used. States in Brazil (b) and departments in Colombia (d) are
arranged by region and then by latitude from North to South.
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resurgence (trough duration) would likely be longer than the
assumed one-year duration of cross-protection. In all scenarios,
suppression of DENV transmission resulted in subsequent
increases in DENV prevalence, suggesting that the low period of
incidence observed in 2017 may be followed by large increases in
DENV.
We also tested the impact of correlation in ZIKV and DENV
transmission intensity on observed associations between cumu-
lative ZIKV and DENV incidence (see Supplementary Fig. 10).
We consistently observed a reduced impact of ZIKV on dengue in
simulations where DENV transmissibility was assumed to be
higher. When the transmissibility of ZIKV and DENV were
assumed to be equal, reductions in DENV due to cross protection
were not larger in simulations with higher ZIKV attack rates as
the impact of ZIKV was offset by increased DENV transmissi-
bility. These results are consistent with an unclear or variable
relationship between DENV reductions and cumulative ZIKV
incidence as we have observed in the data.
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Fig. 2 Comparison between predicted and observed dengue incidence. Results for 2014–2017 are shown for Brazil (a, b) and Colombia (c, d) (see
Supplementary Fig. 5 and 6 for full time series). b, d Red or blue indicate that the observed incidence fell above or below the median of 500 draws from the
posterior of predicted values for that biweek. Medium or dark shading indicates that the observed incidence fell outside of the 90 or 95% prediction
interval (PI) for that biweek. a, c The number of biweeks with observations falling below (blue) or above (red) the 90% PI are displayed with a quantile of
the observed number of significant biweeks out of a distribution generated by 10,000 bootstrapped replicates. In these replicates, year labels were
randomly re-assigned for each location before counting the biweeks in each year that were above or below the 90% PI (see “Methods” for further details).
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Discussion
In 2017, low dengue incidence rates (Fig. 1), atypically high
numbers of biweeks with lower than expected dengue incidence
(Fig. 2), and negative country-level effects (Fig. 3a and c) indicate
a reduction in dengue incidence in Brazil and Colombia. Utilizing
available Zika case data, we were unable to establish a direct link
between this reduction and the Zika epidemic. It is important to
note that there are limitations to using passive surveillance data
(as we have done here), particularly when novel pathogens are
involved. In the case of ZIKV invasion in the Americas, many
cases that occurred early in the epidemic were not reported, since
it took time to first identify the presence of ZIKV and then to
establish reporting protocols. The unavailability of Zika case
count data during the height of the ZIKV epidemic in northeast
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Fig. 3 Spatial hierarchical biweekly dengue incidence models. Shared coefficients from the year model are highlighted in yellow. Shared effect coefficients
for Brazil (a) and Colombia (c). Zika and chikungunya coefficients are estimated from autoregressive dengue models. Positive (negative) coefficients
indicate increases (decreases) in expected dengue incidence for the year model and indirectly as effects on transmission for the Zika and chikungunya
models. Shared year multipliers for expected dengue incidence are shown for Brazil (b) and Colombia (d). The top row of panels b and d are translated
from coefficients in (a) and (c). Other rows display subnational effects (combined shared and location-specific effects). Mean and 95% credible intervals
(CrI) are shown. Intervals that overlap zero are displayed in gray.
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Brazil, one of the most severely affected regions38, may have
contributed to our inability to identify a relationship between
cumulative Zika cases and observed dengue incidence. In both
Brazil and Colombia, misclassified cases (potentially resulting
from shared symptoms between case definitions of dengue, Zika,
and chikungunya) also may have restricted our ability to detect
such a relationship. Other factors such as climatological effects16
or additional mosquito control efforts1,15 and avoidance behavior
may have played a role in reducing dengue incidence.
Our results demonstrate a significant decline in dengue cases in
2017 in Brazil and Colombia. Studies involving laboratory con-
firmed cases and enhanced serosurveillance (for example Ribeiro
et al.38) will play an important role in pinpointing the mechanism
underlying this reduction. Our simulation results show that
troughs in dengue incidence are followed by atypically high
dengue levels. Atypically low dengue case counts observed in
2017 in Brazil and Colombia suggest that population-level sus-
ceptibility to symptomatic dengue has been building. Such high
levels of susceptibility could fuel large dengue epidemics in
upcoming seasons. As of August, 2019, both Brazil and Colombia
have reported more cases at this point in the year than in all of
2017 and 2018, though their dengue seasons are not complete39.
These early indications are consistent with our expectations of the
impact of higher levels of susceptibility due to lower incidence in
recent years.
Methods
Data sources. We collated data from Brazil (27 states) and Colombia (32
departments) into a public data repository25. For Brazil, monthly dengue data is
available for some states starting in 1986 from the National Health Foundation-
FUNASA and for all 27 states starting in 1999. We used monthly data from 1999 to
2012. Monthly data for 2001–2012 were taken from the centralized System for
Reporting of Notifiable Conditions (SINAN)33. For 2013–2017, we entered weekly
data found in the Epidemiological Bulletins34 published by the Secretariat of Health
Surveillance in the Ministry of Health, Brazil where the number of probable cases,
severe dengue, dengue with alarm symptoms, and dengue deaths were reported.
Severe dengue and dengue with alarm symptoms cases are clinically diagnosed
based on symptoms. Case definitions have changed over time, but we use probable
case counts (including both confirmed and unconfirmed cases) in all of our ana-
lyses. Zika and chikungunya case counts were first reported in the Epidemiological
bulletins for Epidemiological week (Epiweek) 13, 2016 and Epiweek 9, 2016
respectively.
Data entry accuracy was checked by re-entering 10% of the weekly bulletins.
Within these bulletins, we found that less than 0.01% of the numeric fields entered
were inconsistent between the primary and secondary entries.
The Epidemiological Bulletins published in Brazil for 2014–2017 also report the
corresponding dengue data for the previous year. We use the available previous
year data reported in the 2014–2018 bulletins to obtain probable dengue case
counts for 2013–2017 Epiweek 42 since these data are most comparable to the
preceding historical data. Analogous updated probable Zika and chikungunya case
counts were first reported in 2017 and 2016 respectively. We use these updated
counts in our analyses. We also use data on the cumulative number of
microcephaly cases and other central nervous system disorders in newborns40
reported in Brazil since Epiweek 45, 2015 through the end of 2016. Cumulative
number of cases later disregarded from the system was also reported. We therefore
deduct the disregarded counts from the case counts.
For Colombia, we use weekly department-level probable dengue case count data
from the Colombian Instituto Nacional de Salud (INS) website35. This dataset
includes weekly dengue case counts for 2007–2017, with severe dengue cases
reported separately for 2014–2017. We excluded cases with an unknown
department and those that were considered imported from other countries. We
combined counts for districts with the counts for the department in which they are
located, whenever they were reported separately. We extracted additional data for
probable Zika and chikungunya cases from the weekly Epidemiological Bulletins36
for 2015–2017. According to the Epidemiological Bulletins published by
Colombia’s Directorate of Surveillance and Risk Analysis in Public Health, Zika has
been in the country since 2015 Epiweek 40 with the number of cases first reported
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in the 2016 Epiweek 1 bulletin. In the updated Colombia dataset, the first
documented Zika cases were in 2015 Epiweek 25. Case counts in the bulletins of
both countries were given as cumulative counts.
We also gathered subnational level population size data for both Brazil and
Colombia25 from the Instituto Brasileiro de Geografia e Estatística41 and
Departamento Administrativo Nacional de Estadística Colombia42 respectively.
Incidence time-series construction. We construct biweekly time series for
probable dengue, Zika, and chikungunya case counts for each state in Brazil and
department in Colombia. The Epidemiological Bulletins provide estimates for the
cumulative number of cases since Epiweek 1 reported up until the corresponding
Epiweek. These cumulative counts are not fixed and are updated as new infor-
mation becomes available, such as updated knowledge of clinical symptoms or
related test results. When the diagnosis of a case is changed to another disease or
when samples are negative for the originally designated pathogen, these cases are
removed from the cumulative counts. Thus, the published cumulative counts
sometimes decrease in consecutive bulletins.
To avoid negative biweekly incidence values, we constructed strictly
nondecreasing upper, middle, and lower approximations of the cumulative time
series. Working backward from the most recent time point, we accounted for
decreases in the cumulative count by either subtracting the difference from all
previous time points (lower approximation) or by setting the higher incidence
equal to the lower incidence in the following biweek (upper approximation). This
process was repeated for all time points, resulting in a strictly nondecreasing time
series. The middle approximation is constructed by averaging the values of the
upper and lower approximation at each time point.
To determine which approximation to use in our analyses, we calculated the
sum of squared errors for each of the approximations using the updated previous
year data (2014–2016) reported in the 2015–2017 Epidemiological Bulletins from
Brazil. We found that the middle approximation best represented our target time
series; this approximation was thus used for the construction of all case count time
series for both Brazil and Colombia. For Brazil, we use the final (updated previous
year) data to construct our time series, when it is available. When performing our
analysis, we used updated data for Brazil up through Epiweek 42, 2017 (since
updated data for the rest of 2017 was unavailable).
For each location and disease, we fit a spline to the adjusted cumulative
incidence curve by using the smooth.spline function from the stats package in R. A
knot was assigned to each data point. We used a binning procedure to translate the
continuous spline into a biweekly sequence of predicted case counts. Cases were
assigned to biweeks with probabilities based on the difference in predicted case
counts at endpoints of consecutive biweeks. When consecutive predicted spline
values decreased, the probability of assigning cases to the first biweek was set to
zero. We repeated the reassignment process 1000 times to create 1000 case count
time-series and then calculated the mean incidence for each biweek (averaged over
the 1000 simulations), rounded down to the nearest integer to obtain the final
biweekly case count. In what follows, we refer to this value as the observed
incidence.
Seasonality evaluation. For each dengue season, we identified the biweeks with
the three greatest numbers of cases in each subnational location (states in Brazil
and departments in Colombia). In Brazil, dengue seasons were defined to range
from biweek 18 to biweek 17 of the next year, to avoid splitting the season into
multiple years. In Colombia, there was not a clear start and end of a dengue season,
so we did not define a particular season that spans across multiple calendar years.
See Supplementary Fig. 1 which describes the seasonality for states and regions.
Time series models. For each year of available data, we fit a seasonal one-step
autoregressive model43 with negative binomial errors for each state in Brazil and
each department in Colombia using incidence data from that location in all other
years. For each location, the number of dengue cases in the following biweek is
modeled as follows:
Cj;tþ1  NB λj;t ; θ
 
ð1Þ
log λj;t ¼ β0 þ βj log Cj;t þ 1
 
þ logNt ð2Þ
where β0 is an intercept, seasonality is incorporated in the form of βj a multi-
plicative factor scaling transmission for biweek t in biweek category
j 2 f1; ¼ ; 26g, Cj, t is the number of probable dengue cases in biweek t, Nt is the
population size (specific to the year and location), and θ is the dispersion para-
meter. We did not fit a separate model for Vaupés, Colombia, since there are no
probable dengue case counts reported for this department in 2007, 2008, 2009,
2011, and 2015. We also did not fit any regression models for the capital of
Colombia, Bogotá, since there is limited corresponding dengue incidence and these
cases are considered to originate from other departments.
Fitting procedure and model performance. We fit all time series models using the
rstanarm R package44 by implementing Bayesian MCMC methods. For each
model, we sampled four chains with 10,000 iterations each (5,000 iterations
included as warmup) for subnational level models and 10,000 iterations each
for national models. Convergence was evaluated by using the launch_shinystan
function of the rstanarm R package44. We primarily assessed the convergence
of our models using the Gelman-Rubin convergence statistic45 and deemed con-
vergence adequate when R^ is less than 1.1. We also checked to see whether there
were any parameters with an effective sample size less than 10% of the total sample
size or any parameters with a Monte Carlo standard error greater than 10% of the
posterior standard deviation. We noted whether there were any divergent transi-
tions after the warmup period. We evaluated model performance by calculating R2
values for the focal year of predictions (out-of-sample values) and predictions of
the data used to fit the models (in-sample values) (see Supplementary Fig. 3).
Comparisons between predicted and observed dengue incidence. Starting with
the second biweek of data for a given location, we sampled 500 values from the
posterior distribution for predicted incidence for the corresponding model (fit
using data from all other years). We evaluated the median prediction for each
biweek and visually compared this value to the number of observed dengue cases in
that biweek (Supplementary Fig. 4). We then evaluated the quantile of the observed
incidence in that biweek in the cumulative distribution of posterior predicted
values. We consider the observed state- or department-level incidence in a parti-
cular biweek to be statistically atypical if it falls outside of the 90% prediction
interval (PI), i.e., if the observed quantile is less than 0.05 or greater than 0.95
(see Fig. 2 and Supplementary Fig. 5). We repeated this analysis using a Bonferroni
adjusted quantile (Supplementary Fig. 6).
Further, we implemented a permutation test to consider whether the number of
atypically high or low observed incidence values in each year (separately for each
country) was significant. For each location, we reassigned the years (sampling
without replacement). Then for each year we counted the number of statistically
high or low values of observed incidence. We repeated this procedure 10,000 times
and then found the quantile of the observed numbers of atypically high or low
biweeks within the cumulative distribution function generated from the permuted
data (see Fig. 2a, c). This permutation procedure preserves temporal correlation
within the years. We considered a second permutation test that preserved spatial
correlation within each biweek. For this test, we reassigned biweek labels. For each
biweek, we sampled without replacement from the years of available predictions for
the corresponding biweek category (ranging from 1–26). We then reassigned the
quantiles of that particular biweek to be the corresponding incidence from that
biweek category in the resampled year. Again, we performed 10,000 permutations
and found the quantile of the observed counts of statistically high or low biweeks in
the corresponding cumulative distribution function. Results were similar between
the two permutation tests. Between the two tests, quantile differences for each year
were less than 5% (median value 0.012, n= 58) and significant results (q > 95%)
presented in Fig. 2 were maintained. Note that we did not include 1999 in the
permutation test for Brazil since data is not available for the entire year in Acre (the
first dengue case in the dataset is in August 1999).
Hierarchical regression models. Separately for Brazil and Colombia, we fit a set
of spatial hierarchical models for dengue incidence (using state-level data for Brazil
models and department-level data for Colombia models) with negative binomial
errors. We considered models with either a log-additive effect for recent years
(2015, 2016, 2017) or a multiplicative effect of either Zika or chikungunya case
counts (previous biweek or total count recorded up to and including the previous
biweek) on expected dengue cases. We focus on an absolute incidence version of
the year effect model, where a dengue seasonality (biweek) indicator is used instead
of the log-dengue case count predictor used in the other models. The subnational
location-specific effects account for deviation from the country-level shared effects.
During the fitting procedure, a variance term is also fit for the distribution of
location-specific effects. These models take the following form:
Ci;j;tþ1  NB λi;j;t ; θ
 
ð3Þ
Additive model:
log λi;j;t ¼ β0 þ βi;j þ αyear tð Þ þ αi;yearðtÞ þ logNi;t ð4Þ
αi;year  N 0; σyear
 
ð5Þ
Multiplicative model:
log λi;j;t ¼ β0 þ βi;j log Ci;j;t þ 1
 
þ ðαþ αiÞlogðXi;t þ 1Þ þ logNi;t ð6Þ
αi  N 0;ϕð Þ ð7Þ
In the additive model, αyear represents the shared effect for 2015, 2016, and
2017. αi, year and αi are location-specific (subnational) terms for the additive
year effect and multiplicative arbovirus-related incidence effect respectively (with
dispersion parameters αyear and ϕ). There is one intercept coefficient (β0) and one
coefficient for each state biweek pair (βi. j), where i ranges over the subnational
locations and j ranges over the 26 biweeks. These coefficients allow for seasonal
differences in transmission intensity at the subnational level. Additionally, there is
an offset for year-specific subnational population size (Ni,t). Xi,t represents either:
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Zika or chikungunya incidence (either at biweek t or the cumulative total number
of cases reported up through biweek t in location i). We consider year and
arbovirus-related incidence coefficients to be significant when their 95% Bayesian
credible interval (CrI) does not overlap zero.
Stochastic compartmental model. We developed a four serotype DENV model
that also allowed for ZIKV infection in both mosquito and human populations.
There are six mosquito compartments: susceptible, infected with one of the four
dengue serotypes, and infected with ZIKV. The human compartments are based on
both DENV and ZIKV status. With respect to DENV infection status, individuals
in the human population are either susceptible, infectious, cross-protected, or
recovered. We keep track of primary and secondary DENV infections and assume
that after two heterotypic DENV infections, individuals become immune to further
DENV infections. Homotypic reinfections are not allowed in the model. The
human classes are further stratified depending on the individual’s ZIKV status:
either susceptible, infectious, cross-protected (from DENV), or recovered. There
are 125 total compartments in the model.
We considered a suite of immune-mediated interaction scenarios, considering
the possibility of enhancement or cross-protection. The enhancement scenarios we
considered included: no enhancement, DENV enhances DENV, DENV enhances
DENV and ZIKV, and enhancement in all directions. Enhancement was
incorporated as a 1.6-fold increase in the force of infection from humans to
mosquitos. We incorporated a symmetric cross-protective effect, i.e. for a period of
time, a dengue infection would reduce the hazard of a future Zika infection and a
Zika infection would reduce the hazard of a future dengue infection. Cross-
serotype dengue protection (80% hazard reduction to other DENV serotypes)
was included in all scenarios. The average duration of cross-protection between
DENV serotypes was one year (γ= 1)46. We considered the case when cross-
protection between dengue and Zika also lasted one year on average. The scenarios
without cross-protection did allow for a reduced hazard for approximately 4 days
(γ= 1/100). We considered two levels of cross-protection between DENV and
ZIKV. The high-level matched the level of cross-serotype dengue protection (ρ=
0.2)46. The low-level of cross-protection reduced the hazard for the other virus by
only 20% (ρ= 0.8). We did not incorporate seasonality in either DENV or ZIKV
transmission but expect simulations with seasonality to be qualitatively similar to
those presented here.
We ran 100 simulations for each scenario using a tau-leap approximation of the
Gillespie method in Fortran. ZIKV was introduced into the mosquito population
after 100 years of DENV only simulations. Numerical solutions for the
corresponding deterministic system (using randomized initial conditions)
simulated for a period of 600 years (to approximate steady state) were used to
determine the initial conditions for the stochastic simulations mentioned here. An
additional 20 years of data was simulated after the introduction of ZIKV. We
considered DENV and ZIKV reproduction numbers for all combinations of 2 and
4 (see Fig. 4 for the case when DENV and ZIKV reproduction numbers are 4 and 2
respectively), and for the case when both are set to 3 (see Supplementary Fig. 10).
The human population size was 10 million and the mosquito population size was
20 million (ratio of total mosquito population to human population set to 2)47. The
human death rate was 0.02 per year48 and the mosquito death rate was 15 per
year49. Simulation data analysis was performed in R.
We also considered the case when ZIKV was introduced after 40 years of DENV
only simulations (see Supplementary Figs. 11 and 12). For these simulations,
introduction of DENV1-4 infected mosquitoes are introduced according to Poisson
processes with rate parameter such that on average three infected mosquitoes are
introduced each year for each serotype. Sample simulations displaying DENV
dynamics prior to the introduction of ZIKV under both stable and recently
introduced DENV conditions are displayed in Supplementary Fig. 12.
To evaluate the effects of incorporating cross-protection or enhancement, we
consider changes in trough duration and peak size. All scenarios that incorporated
an immune-mediated interaction were evaluated against the baseline determined
by the scenario with no enhancement and no cross-protection between DENV and
ZIKV (see Fig. 4a). We define the trough duration to be the length of time that
aggregated DENV prevalence is consecutively less than one half of the average
incidence following the introduction of ZIKV, in the baseline scenario
(approximately 16 individuals per 100,000 population). We set the trough duration
to zero for all simulations that did not include a complete trough within the
20 years following the introduction of ZIKV. Peak size is defined to be the
maximum DENV prevalence value, aggregated across all serotypes, in the 20 years
following the introduction of ZIKV. Changes in peak size resulting from
incorporating cross-protection between DENV and ZIKV were evaluated by
dividing the average peak size for scenarios without enhancement by the average
peak size in the baseline case (where the average is taken across the 100 simulations
of each scenario). Peak size and trough duration averages and inter-quantile ranges
across the 100 simulations of each scenario are displayed in Supplementary Table 1.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Code availability
The code used to process the case count data and to produce our results is available in
GitHub repository UF-IDD/dengue-Zika-chik_Americas [https://github.com/UF-IDD/
dengue-Zika-chik_Americas] (ref. 25).
Data availability
The case count and population data gathered and analyzed in this study are available in
GitHub repository UF-IDD/dengue-Zika-chik_Americas [https://github.com/UF-IDD/
dengue-Zika-chik_Americas] (ref. 25).
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